(WASHINGTON, May 7, 2012) – A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter ...
An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic immune thrombocytopenic purpura (ITP), highlighting proactive strategies like ...
Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results